Showing results (31-40 of 151) with videos related to
Sort By:
Pageof 16
International Journal of Molecular Sciences|November 11, 2022
FcγRs and Their Relevance for the Activity of Anti-CD40 AntibodiesIsabell Lang, Olena Zaitseva, Harald WajantMethods in Molecular Biology (Clifton, N.J.)|January 13, 2017
Generation and Application of Bioluminescent CD95 Ligand Fusion ProteinsIsabell Lang, Juliane Kums, Harald WajantCancers|June 10, 2022
Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer TherapyJuliane Medler, Kirstin Kucka, Harald WajantFrontiers in Immunology|May 10, 2018
Lack of Evidence for a Direct Interaction of Progranulin and Tumor Necrosis Factor Receptor-1 and Tumor Necrosis Factor Receptor-2 From Cellular Binding StudiesIsabell Lang, Simone Füllsack, Harald WajantCell Death & Disease|September 13, 2018
TNFR2 unlocks a RIPK1 kinase activity-dependent mode of proinflammatory TNFR1 signalingDaniela Siegmund, Martin Ehrenschwender, Harald WajantResults and Problems in Cell Differentiation|January 15, 2009
Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligandsJeannette Gerspach, Harald Wajant, Klaus PfizenmaierMethods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Production, purification, and characterization of scFv TNF ligand fusion proteinsAndrea Fick, Agnes Wyzgol, Harald WajantBiochemical and Biophysical Research Communications|May 8, 2010
Superior serum half life of albumin tagged TNF ligandsNicole Müller, Britta Schneider, Klaus Pfizenmaier, et al.Cell Death & Disease|February 12, 2019
Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signalingSimone Füllsack, Alevtina Rosenthal, Harald Wajant, et al.Frontiers in Pharmacology|November 7, 2022
Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapyOlena Zaitseva, Annett Hoffmann, Christoph Otto, et al.Pageof 16